UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma (Nasdaq: URGN), a biotechnology company focused on urothelial and specialty cancer treatments, has announced its participation in three upcoming investor conferences in September 2025.
The company will participate in fireside chat sessions at the Wells Fargo Healthcare Conference in Boston on September 3rd at 2:15 PM ET, the Cantor Fitzgerald Global Healthcare Conference in New York on September 4th at 3:55 PM ET, and the H.C. Wainwright Global Healthcare Conference in New York on September 8th at 9:00 AM ET.
Webcasts will be accessible through UroGen's Investor Relations website, with replays available for approximately 90 days after each event.
UroGen Pharma (Nasdaq: URGN), società biotecnologica specializzata in terapie per tumori uroteliali e oncologia specialistica, ha comunicato la sua partecipazione a tre conferenze per investitori previste a settembre 2025.
L’azienda prenderà parte a sessioni tipo "fireside chat" al Wells Fargo Healthcare Conference a Boston il 3 settembre alle 14:15 ET, al Cantor Fitzgerald Global Healthcare Conference a New York il 4 settembre alle 15:55 ET e all’H.C. Wainwright Global Healthcare Conference a New York l’8 settembre alle 09:00 ET.
I webcast saranno disponibili tramite il sito Investor Relations di UroGen, con le registrazioni fruibili per circa 90 giorni dopo ciascun evento.
UroGen Pharma (Nasdaq: URGN), una compañía biotecnológica centrada en tratamientos para cáncer urotelial y oncología especializada, ha anunciado su participación en tres conferencias para inversores en septiembre de 2025.
La compañía participará en charlas tipo "fireside" en el Wells Fargo Healthcare Conference en Boston el 3 de septiembre a las 2:15 PM ET, en el Cantor Fitzgerald Global Healthcare Conference en Nueva York el 4 de septiembre a las 3:55 PM ET y en el H.C. Wainwright Global Healthcare Conference en Nueva York el 8 de septiembre a las 9:00 AM ET.
Los webcasts se podrán seguir a través de la web de Relaciones con Inversores de UroGen, y las grabaciones estarán disponibles aproximadamente 90 días tras cada evento.
UroGen Pharma (Nasdaq: URGN)는 요로상피암 및 전문 암 치료에 주력하는 바이오테크 기업으로, 2025년 9월 개최되는 세 차례 투자자 컨퍼런스에 참여할 예정임을 발표했습니다.
회사는 9월 3일 오후 2시 15분(ET) 보스턴에서 열리는 Wells Fargo Healthcare Conference, 9월 4일 오후 3시 55분(ET) 뉴욕의 Cantor Fitzgerald Global Healthcare Conference, 그리고 9월 8일 오전 9시(ET) 뉴욕의 H.C. Wainwright Global Healthcare Conference에서 파이어사이드 채팅 세션에 참석합니다.
웹캐스트는 UroGen의 투자자 관계 웹사이트를 통해 시청할 수 있으며, 각 행사 종료 후 약 90일간 다시보기 서비스를 제공합니다.
UroGen Pharma (Nasdaq: URGN), une société biotechnologique spécialisée dans les traitements des cancers urothéliaux et en oncologie spécialisée, a annoncé sa participation à trois conférences investisseurs en septembre 2025.
La société prendra part à des sessions de type « fireside chat » lors du Wells Fargo Healthcare Conference à Boston le 3 septembre à 14h15 ET, du Cantor Fitzgerald Global Healthcare Conference à New York le 4 septembre à 15h55 ET et du H.C. Wainwright Global Healthcare Conference à New York le 8 septembre à 9h00 ET.
Les webcasts seront accessibles via le site des relations investisseurs d’UroGen, avec des replays disponibles pendant environ 90 jours après chaque événement.
UroGen Pharma (Nasdaq: URGN), ein Biotechnologieunternehmen mit Fokus auf uroteliale und spezialisierte Krebstherapien, hat seine Teilnahme an drei Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird an Fireside-Chat-Sitzungen teilnehmen: beim Wells Fargo Healthcare Conference in Boston am 3. September um 14:15 Uhr ET, beim Cantor Fitzgerald Global Healthcare Conference in New York am 4. September um 15:55 Uhr ET und beim H.C. Wainwright Global Healthcare Conference in New York am 8. September um 09:00 Uhr ET.
Webcasts sind über die Investor-Relations-Website von UroGen zugänglich, Replays stehen jeweils für etwa 90 Tage nach den Veranstaltungen zur Verfügung.
- None.
- None.
PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September.
Wells Fargo Healthcare Conference
| Date / Time: | September 3rd, at 2:15 PM ET |
| Format: | Fireside Chat |
| Location: | Boston, MA |
Cantor Fitzgerald Global Healthcare Conference
| Date / Time: | September 4th, at 3:55 PM ET |
| Format: | Fireside Chat |
| Location: | New York, NY |
H.C. Wainwright 27th Annual Global Healthcare Conference
| Date / Time: | September 8th, at 9:00 AM ET |
| Format: | Fireside Chat |
| Location: | New York, NY |
The conference webcasts will be available through the Events section of the Company’s Investor Relations website. Replays will be available for approximately 90 days following the event.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is the first and only FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X (Twitter), @UroGenPharma.
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
FAQ
When is UroGen Pharma (URGN) presenting at the Wells Fargo Healthcare Conference 2025?
How can investors access UroGen Pharma's (URGN) conference presentations in September 2025?
Which investor conferences is UroGen Pharma (URGN) attending in September 2025?
What is the format of UroGen Pharma's (URGN) presentations at the September 2025 conferences?
